What happened to anti-malarial markets after the Affordable Medicines Facility-malaria pilot? Trends in ACT availability, price and market share from five African countries under continuation of the private sector co-payment mechanism

by ACTwatch Group, Sarah Tougher, Kara Hanson and Catherine Goodman
Malaria Journal201716:173 – Published: 25 April 2017

18 pp. 1.5 MB
https://malariajournal.biomedcentral.com/track/pdf/10.1186/s12936-017-1814-z?
site=malariajournal.biomedcentral.com

The private sector supplies anti-malarial treatment for large proportions of patients in sub-Saharan Africa. Following the large-scale piloting of the Affordable Medicines Facility-malaria (AMFm) from 2010 to 2011, a private sector co-payment mechanism (CPM) provided continuation of private sector subsidies for quality-assured artemisinin combination therapies (QAACT). This article analyses for the first time the extent to which improvements in private sector QAACT supply and distribution observed during the AMFm were maintained or intensified during continuation of the CPM through 2015 in Kenya, Madagascar, Nigeria, Tanzania and Uganda using repeat cross-sectional outlet survey data.

(Visited 5 times, 1 visits today)
This entry was posted in Essential Medicines, General, Malaria. Bookmark the permalink.